Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: Evidence for multiple resistance mechanisms

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3079-3085

  Yang, Soo Jin ^a   Nast, Cynthia C ^b,c   Mishra, Nagendra N ^a   Yeaman, Michael R ^a,c   Fey, Paul D ^d   Bayer, Arnold S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; GENE EXPRESSION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BLOOD; CELL WALL; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; MUTATION; OCTOXYNOL; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS;

EID: 77955352834     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00122-10     Document Type: Article

References (40)

1. Bharat, L. D., and M. G. Chhitar. 1998. Role of the actin cytoskeleton in regulating the outer phosphatidylethanolamine levels in yeast plasma membrane. Eur. J. Biochem. 254:202-206.
2. Boucher, H. W., and G. Sakoulas. 2007. Antimicrobial resistance: perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608.
3. Brunskill, E. W., and K. W. Bayles. 1996. Identification and molecular characterization of a putative regulatory locus that affects autolysis in Staphylococcus aureus. J. Bacteriol. 178:611-618.
4. Camargo, I. L, H.-M. Neoh, L. Cui, and K. Hiramatsu. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-4299.
5. Collins, L. V., S. A. Kristian, C. Weidenmaier, M. Faigle, K. P. M. van Kessel, J. A. G. van Strijp, F. Gotz, B. Neumeister, and A. Peschel. 2002. Staphylococcus aureus strains lacking d-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186:214-219.
6. Cui, L., E. Tominaga, H.-M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
7. Ernst, C., P. Staubitz, N. N. Mishra, S. J. Yang, G. Hornig, H. Kalbacher, A. S. Bayer, D. Kraus, and A. Peschel. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLos Pathog. 5:e1000660.
8. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
9. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
10. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
11. Jones, T., M. R. Yeaman, G. Sakoulas, S. J. Yang, R. A. Proctor, H. G. Sahl, J. Schrenzel, Y. Q. Xiong, and A. S. Bayer. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
12. Julian, K., K. Kosowska-Shick, C. Whitener, M. Roos, H. Labischinski, A. Rubio, L. Parent, L. Ednie, L. Koeth, T. Bogdanovich, and P. C. Appelbaum. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
13. Lalani, T., J. J. Federspiel, H. W. Boucher, T. H. Rude, I.-G. Bae, M. J. Rybak, G. T. Tonthat, G. R. Corey, M. E. Stryjewski, G. Sakoulas, V. H. Chu, J. Alder, J. N. Steenbergen, S. A. Luperchio, M. Campion, C. W. Woods, and V. G. Fowler. 2008. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J. Clin. Microbiol. 46:2890-2896.
14. Mariani, P. G., H. S. Sader, and R. N. Jones. 2006. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 58:481-483.
15. Meehl, M., S. Herbert, F. Gotz, and A. Cheung. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689.
16. Mishra, N. N., S. J. Yang, A. Sawa, A. Rubio, C. C. Nast, M. R. Yeaman, and A. S. Bayer. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA). Antimicrob. Agents Chemother. 53:2312-2318.
17. Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:1262-1266.
18. Mukhopadhyay, K., W. Whitmire, Y. Q. Xiong, J. Molden, T. Jones, A. Peschel, P. Staubitz, J. Adler-Moore, P. J. McNamara, R. A. Proctor, M. R. Yeaman, and A. S. Bayer. 2007. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153:1187-1197.
19. Murthy, M. H., M. E. Olson, R. E. Wickert, P. D. Fey, and Z. Jalali. 2008. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J. Med. Microbiol. 57:1036-1038.
20. Oku, Y., K. Kurokawa, N. Ichihashi, and K. Sekimizu. 2004. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology 150:45-51.
21. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410.
22. Pillai, S. K., H. S. Gold, G. Sakoulas, C. Wennersten, R. C. Moellering, Jr., and G. M. Eliopoulos. 2007. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob. Agents Chemother. 51:2223-2225.
23. Sakoulas, G., G. M. Eliopoulos, J. Alder, and C. T. Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
24. Schriever, C. A., C. Fernandez, K. A. Rodvold, and L. H. Danziger. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158.
25. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
26. Skiest, D. J. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656.
27. Staubitz, P., H. Neumann, T. Schneider, I. Wiedemann, and A. Peschel. 2004. MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance. FEMS Microbiol. Lett. 231:67.
28. Steenbergen, J. N., J. Alder, G. M. Thorne, and F. P. Tally. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 55:283-288.
29. Straus, S. K., and R. E. W. Hancock. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215.
30. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
31. Weidenmaier, C., A. Peschel, V. A. J. Kempf, N. Lucindo, M. R. Yeaman, and A. S. Bayer. 2005. DltABCD- and MprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect. Immun. 73:8033-8038.
32. Wootton, M., A. P. MacGowan, and T. R. Walsh. 2006. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob. Agents Chemother. 50:4195-4197.
33. Xiong, Y. Q., A. S. Bayer, L. Elazegui, and M. R. Yeaman. 2006. A synthetic congener modeled on a microbicidal domain of thrombin-induced platelet microbicidal protein-1 recapitulates staphylocidal mechanisms of the native molecule. Antimicrob. Agents Chemother. 50:3786-3792.
34. Xiong, Y. Q., K. Mukhopadhyay, M. R. Yeaman, J. Adler-Moore, and A. S. Bayer. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121.
35. Yang, S.-J., K. C. Rice, R. J. Brown, T. G. Patton, L. E. Liou, Y. H. Park, and K. W. Bayles. 2005. A LysR-type regulator, CidR, is required for induction of the Staphylococcus aureus cidABC operon. J. Bacteriol. 187:5893-5900.
36. Yang, S. J., B. N. Kreiswirth, G. Sakoulas, M. R. Yeaman, Y. Q. Xiong, A. Sawa, and A. S. Bayer. 2009. Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
37. Yang, S. J., Y. Q. Xiong, P. M. Dunman, J. Schrenzel, P. Francois, A. Peschel, and A. S. Bayer. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2636-2637.
38. Yeaman, M. R., A. S. Bayer, S.-P. Koo, W. Foss, and P. M. Sullam. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Invest. 101:178-187.
39. Yeaman, M. R., K. D. Gank, A. S. Bayer, and E. P. Brass. 2002. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46:3883-3891.
40. Yeaman, M. R., S. M. Puentes, D. C. Norman, and A. S. Bayer. 1992. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect. Immun. 60:1202-1209.